Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D001161:Arteriosclerosis / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D006328:Cardiac Catheterization / Q000009:adverse effects; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control*; D014184:Transplantation, Homologous
D005343:Fibrinolytic Agents; D004176:Dipyridamole; D002994:Clofibrate; D001241:Aspirin; D013442:Sulfinpyrazone